Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Echinobase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
Echinobase
ECB-ART-52661
Crit Care 2023 Nov 09;271:435. doi: 10.1186/s13054-023-04720-2.
Show Gene links Show Anatomy links

Moving toward a contemporary classification of drug-induced kidney disease.

Karimzadeh I , Barreto EF , Kellum JA , Awdishu L , Murray PT , Ostermann M , Bihorac A , Mehta RL , Goldstein SL , Kashani KB , Kane-Gill SL .


Abstract
Drug-induced kidney disease (DIKD) accounts for about one-fourth of all cases of acute kidney injury (AKI) in hospitalized patients, especially in critically ill setting. There is no standard definition or classification system of DIKD. To address this, a phenotype definition of DIKD using expert consensus was introduced in 2015. Recently, a novel framework for DIKD classification was proposed that incorporated functional change and tissue damage biomarkers. Medications were stratified into four categories, including "dysfunction without damage," "damage without dysfunction," "both dysfunction and damage," and "neither dysfunction nor damage" using this novel framework along with predominant mechanism(s) of nephrotoxicity for drugs and drug classes. Here, we briefly describe mechanisms and provide examples of drugs/drug classes related to the categories in the proposed framework. In addition, the possible movement of a patient's kidney disease between certain categories in specific conditions is considered. Finally, opportunities and barriers to adoption of this framework for DIKD classification in real clinical practice are discussed. This new classification system allows congruencies for DIKD with the proposed categorization of AKI, offering clarity as well as consistency for clinicians and researchers.

PubMed ID: 37946280
Article link: Crit Care



References [+] :
Awdishu, The 6R's of drug induced nephrotoxicity. 2017, Pubmed